CN112243438A - 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物 - Google Patents

作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物 Download PDF

Info

Publication number
CN112243438A
CN112243438A CN201980040052.2A CN201980040052A CN112243438A CN 112243438 A CN112243438 A CN 112243438A CN 201980040052 A CN201980040052 A CN 201980040052A CN 112243438 A CN112243438 A CN 112243438A
Authority
CN
China
Prior art keywords
compound
alkyl
membered heterocycloalkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980040052.2A
Other languages
English (en)
Other versions
CN112243438B (zh
Inventor
张杨
王建非
谭海忠
李婕
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Medshine Discovery Inc filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202210418417.4A priority Critical patent/CN114716455A/zh
Publication of CN112243438A publication Critical patent/CN112243438A/zh
Application granted granted Critical
Publication of CN112243438B publication Critical patent/CN112243438B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发公开了一类IRAK4抑制剂，及其在制备治疗与IRAK4相关疾病的药物中的应用。具体公开了式（Ⅲ）所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201980040052.2A 2018-06-25 2019-06-25 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物 Active CN112243438B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210418417.4A CN114716455A (zh) 2018-06-25 2019-06-25 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810662580 2018-06-25
CN2018106625809 2018-06-25
CN201910463156 2019-05-30
CN2019104631566 2019-05-30
PCT/CN2019/092867 WO2020001449A1 (zh) 2018-06-25 2019-06-25 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210418417.4A Division CN114716455A (zh) 2018-06-25 2019-06-25 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物

Publications (2)

Publication Number Publication Date
CN112243438A true CN112243438A (zh) 2021-01-19
CN112243438B CN112243438B (zh) 2022-03-15

Family

ID=68986119

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980040052.2A Active CN112243438B (zh) 2018-06-25 2019-06-25 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物
CN202210418417.4A Pending CN114716455A (zh) 2018-06-25 2019-06-25 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210418417.4A Pending CN114716455A (zh) 2018-06-25 2019-06-25 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物

Country Status (13)

Country Link
US (1) US11459337B2 (zh)
EP (1) EP3816164B9 (zh)
JP (1) JP7511489B2 (zh)
KR (1) KR20210024543A (zh)
CN (2) CN112243438B (zh)
AU (1) AU2019296118B2 (zh)
BR (1) BR112020026507A8 (zh)
CA (1) CA3104380A1 (zh)
DK (1) DK3816164T5 (zh)
ES (1) ES2978674T3 (zh)
HU (1) HUE066411T2 (zh)
PL (1) PL3816164T3 (zh)
WO (1) WO2020001449A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3167676A1 (en) * 2020-01-21 2021-07-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Irak4 inhibitor crystal and preparation method therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106232122A (zh) * 2013-09-27 2016-12-14 林伯士艾瑞斯公司 Irak抑制剂和其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703941B2 (en) 2011-01-10 2014-04-22 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
IN2015DN00127A (zh) 2012-07-11 2015-05-29 Nimbus Iris Inc
WO2017004133A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017186689A1 (en) 2016-04-29 2017-11-02 Bayer Pharma Aktiengesellschaft Synthesis of indazoles
AU2017256659B2 (en) 2016-04-29 2021-05-27 Bayer Pharma Aktiengesellschaft Synthesis of indazoles
WO2017205766A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106232122A (zh) * 2013-09-27 2016-12-14 林伯士艾瑞斯公司 Irak抑制剂和其用途

Also Published As

Publication number Publication date
EP3816164B1 (en) 2024-04-03
CA3104380A1 (en) 2020-01-02
AU2019296118A1 (en) 2020-01-02
EP3816164B9 (en) 2024-07-10
HUE066411T2 (hu) 2024-08-28
JP2021529751A (ja) 2021-11-04
BR112020026507A2 (pt) 2021-03-23
EP3816164A4 (en) 2022-03-16
CN112243438B (zh) 2022-03-15
DK3816164T5 (da) 2024-07-22
KR20210024543A (ko) 2021-03-05
EP3816164A1 (en) 2021-05-05
AU2019296118B2 (en) 2024-09-26
US11459337B2 (en) 2022-10-04
JP7511489B2 (ja) 2024-07-05
US20210269459A1 (en) 2021-09-02
ES2978674T3 (es) 2024-09-17
CN114716455A (zh) 2022-07-08
PL3816164T3 (pl) 2024-08-12
DK3816164T3 (da) 2024-04-22
BR112020026507A8 (pt) 2023-01-31
WO2020001449A1 (zh) 2020-01-02
AU2019296118A8 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CN111484477B (zh) 一种苯并吡啶酮杂环化合物及其用途
KR101864561B1 (ko) Jak 억제제
US7820680B2 (en) HIV integrase inhibitors
CA2818545C (en) Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
KR101982912B1 (ko) 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
CN110945000B (zh) 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途
US20110046130A1 (en) Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
CN116848112A (zh) 吡啶[4，3-d]嘧啶类化合物
US9453021B2 (en) Pyrimidodiazepinone compound
JP2023522725A (ja) ３－アザビシクロアルキル誘導体およびこれを含む薬剤学的組成物
US20240132489A1 (en) Aromatic heterocyclic compound, pharmaceutical composition, and use thereof
CN113004269A (zh) Kras-G12C抑制剂杂环化合物
CN112243438B (zh) 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物
KR101771219B1 (ko) 야누스 키나제 1 선택적 억제제 및 그 의약 용도
CN114075219A (zh) 喹啉稠环类衍生物、其制备方法及其在医药上的应用
US20230040182A1 (en) ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
JP2022534316A (ja) Ｃｄｃ７阻害剤としての四環式化合物
RU2801942C9 (ru) СОЕДИНЕНИЯ НА ОСНОВЕ ИЗОТИАЗОЛО[5,4-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА IRAK4
RU2801942C2 (ru) СОЕДИНЕНИЯ НА ОСНОВЕ ИЗОТИАЗОЛО[5,4-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА IRAK4
CN115003672A (zh) 喹啉并咪唑类化合物及其应用
CA3191617A1 (en) Novel amine derivatives
US10745409B2 (en) Azepane inhibitors of menin-MLL interaction
US11780843B2 (en) Compounds active towards nuclear receptors
US20240317775A1 (en) H4 Antagonist Compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40041605

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210927

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

GR01 Patent grant
GR01 Patent grant